Vistagen Therapeutics, Inc. (VTGN) Form 8-K — Jun 15, 2026
Vistagen Therapeutics reported a net loss of $69.7 million for the fiscal year ended March 31, 2026, compared to a loss of $51.4 million in the prior year. The company ended the period with $45.4 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to fund operations into 2027. Research and development expenses increased to $55.0 million, driven primarily by the PALISADE Program for fasedienol and manufacturing activities. On the operational front, Vistagen completed the randomized portion of its PALISADE-4 Phase 3 trial evaluating fasedienol for the acute treatment of social anxiety disorder, with topline results expected in June 2026.
Key figures
- Revenue
- 1269000
- Cash Position
- 45400000
- Shares Outstanding
- 39624839
- Runway
- into 2027
- Ga Expense
- 18400000
- Rd Expense
- 55000000
Price after filing
Close on the filing date to close N calendar days later (from $0.57). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.